Market cap of Momenta Pharmaceuticals Inc. [MNTA] reaches 3.30B – now what?

Momenta Pharmaceuticals Inc. [NASDAQ: MNTA] price plunged by -13.47 percent to reach at -$4.44. The company report on August 10, 2020 that Momenta Pharmaceuticals Reports Second Quarter 2020 Financial and Operating Results.

— Interim Phase 2 Vivacity-MG results met primary endpoints, demonstrating nipocalimab was well-tolerated and achieved rapid and durable responses with significant correlation (p<0.0001) between IgG reduction and MG-ADL clinical benefit in MG; full data expected by Q4 2020 – . -- Nipocalimab receives rare pediatric disease designation by FDA for HDFN -- . A sum of 2682674 shares traded at recent session while its average daily volume was at 1.14M shares. Momenta Pharmaceuticals Inc. shares reached a high of $32.99 and dropped to a low of $27.78 until finishing in the latest session at $28.55. The one-year MNTA stock forecast points to a potential upside of 36.74. The average equity rating for MNTA stock is currently 2.20, trading closer to a bullish pattern in the stock market.

Guru’s Opinion on Momenta Pharmaceuticals Inc. [MNTA]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for MNTA shares is $45.13 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on MNTA stock is a recommendation set at 2.20. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Cowen have made an estimate for Momenta Pharmaceuticals Inc. shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on August 03, 2020. While these analysts kept the previous recommendation, Goldman raised their target price to Neutral. The new note on the price target was released on March 12, 2020, representing the official price target for Momenta Pharmaceuticals Inc. stock. Previously, the target price had yet another raise to $30, while JP Morgan analysts kept a Overweight rating on MNTA stock.

The Average True Range (ATR) for Momenta Pharmaceuticals Inc. is set at 1.89, with the Price to Sales ratio for MNTA stock in the period of the last 12 months amounting to 115.38. The Price to Book ratio for the last quarter was 7.80, with the Price to Cash per share for the same quarter was set at 4.01.

MNTA Stock Performance Analysis:

Momenta Pharmaceuticals Inc. [MNTA] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -11.76. With this latest performance, MNTA shares dropped by -16.78% in over the last four-week period, additionally sinking by -10.32% over the last 6 months – not to mention a rise of 142.32% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for MNTA stock in for the last two-week period is set at 39.60, with the RSI for the last a single of trading hit 33.69, and the three-weeks RSI is set at 40.92 for Momenta Pharmaceuticals Inc. [MNTA]. The present Moving Average for the last 50 days of trading for this stock 33.22, while it was recorded at 31.77 for the last single week of trading, and 27.16 for the last 200 days.

Insight into Momenta Pharmaceuticals Inc. Fundamentals:

Operating Margin for any stock indicates how profitable investing would be, and Momenta Pharmaceuticals Inc. [MNTA] shares currently have an operating margin of -1133.30. Momenta Pharmaceuticals Inc.’s Net Margin is presently recorded at -1215.25.

Return on Total Capital for MNTA is now -56.64, given the latest momentum, and Return on Invested Capital for the company is -61.08. Return on Equity for this stock declined to -63.37, with Return on Assets sitting at -50.45. When it comes to the capital structure of this company, Momenta Pharmaceuticals Inc. [MNTA] has a Total Debt to Total Equity ratio set at 8.75. Additionally, MNTA Total Debt to Total Capital is recorded at 8.04, with Total Debt to Total Assets ending up at 6.43. Long-Term Debt to Equity for the company is recorded at 7.55, with the Long-Term Debt to Total Capital now at 6.94.

Reflecting on the efficiency of the workforce at the company, Momenta Pharmaceuticals Inc. [MNTA] managed to generate an average of -$2,458,093 per employee. Receivables Turnover for the company is 2.46 with a Total Asset Turnover recorded at a value of 0.04.Momenta Pharmaceuticals Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 5.90 and a Current Ratio set at 5.90.


With the latest financial reports released by the company, Momenta Pharmaceuticals Inc. posted -1.16/share EPS, while the average EPS was predicted by analysts to be reported at -0.42/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -176.20%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for MNTA.

Momenta Pharmaceuticals Inc. [MNTA] Insider Position Details

There are presently around $3,341 million, in the hands of institutional investors. The top three institutional holders of MNTA stocks are: BLACKROCK INC. with ownership of 18,217,622, which is approximately 5.403% of the company’s market cap and around 0.30% of the total institutional ownership; FMR LLC, holding 17,591,341 shares of the stock with an approximate value of $502.14 million in MNTA stocks shares; and VANGUARD GROUP INC, currently with $349.46 million in MNTA stock with ownership of nearly 2.706% of the company’s market capitalization.

Positions in Momenta Pharmaceuticals Inc. stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 140 institutional holders increased their position in Momenta Pharmaceuticals Inc. [NASDAQ:MNTA] by around 18,110,971 shares. Additionally, 75 investors decreased positions by around 15,569,135 shares, while 21 investors held positions by with 83,369,530 shares. The mentioned changes placed institutional holdings at 117,049,636 shares, according to the latest SEC report filing. MNTA stock had 51 new institutional investments in for a total of 9,109,917 shares, while 19 institutional investors sold positions of 971,561 shares during the same period.

Share on facebook
Share on twitter
Share on linkedin
Share on skype
Share on reddit

Leave a Comment

Your email address will not be published. Required fields are marked *

Get The Best Stocks To Trade Every Day!

Join now to get the pre-market morning brief 100% free

We do not sell or share your information with anyone.

Get Notified Of Insider Trades, Analyst Upgrades & Downgrades, Earnings Updates & Best Stocks To Trade Every Single Morning

100% free. stop anytime no spam